You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1137-ESGO Use of an allogeneic, cell-based vaccine DCP-001 in high grade Serous Ovarian cancerpatients after primary treatment; A phase I clinical trial

Citation Tools

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1137-ESGO Use of an allogeneic, cell-based vaccine DCP-001 in high grade Serous Ovarian cancerpatients after primary treatment; A phase I clinical trial
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Vledder A, van Zeeburg H, Pas RT, et al
2022-RA-1137-ESGO Use of an allogeneic, cell-based vaccine DCP-001 in high grade Serous Ovarian cancerpatients after primary treatment; A phase I clinical trial
International Journal of Gynecologic Cancer 2022;32:A304.